1. Introduction
2. Objectives
3. Materials and Methods
3.1. Protocol and Registration
3.2. Search Strategy
| Electronic Databases | Search Strategy | Records |
|---|---|---|
| PubMed/Medline | ((“Cerebrovascular Disorders”[Mesh] OR “Cardiovascular Diseases”[Mesh] OR “cerebrovascular dis*”[Title/Abstract] OR “cardiovascular diseases”[Title/Abstract] OR “CVD”[Title/Abstract] OR “coronary heart disease”[Title/Abstract] OR “CHD”[Title/Abstract] OR “heart disease”[Title/Abstract] OR “myocardial infarction”[Title/Abstract] OR “MI”[Title/Abstract] OR “Adverse Cardiac Event*”[Title/Abstract] OR “cardiovascular death”[Title/Abstract] OR “cardiovascular mortality”[Title/Abstract] OR “stroke”[Mesh] OR “Stroke*”[Title/Abstract] OR "Diabetes Mellitus"[Mesh] OR "cardiometabolic*"[Title/Abstract] OR diabet*[tiab] OR "insulin resistan*"[tiab] OR "glucose intoleran*"[tiab] OR "hyperglycemi*"[tiab] OR "hyperglycemi*"[Mesh] OR “prediab*”[Title/Abstract] OR "impaired glucose tolerance"[tiab] OR "impaired fasting glucose"[tiab] OR dyslipidemia[tiab] OR dyslipidemia[Mesh] OR hypertension[tiab] OR hypertension[Mesh] OR hyperlipidemia[Mesh] OR “Obesity”[Mesh] OR “overweight”[Mesh]) AND ("Diet, Plant-Based" [Mesh] OR "Diet, Vegetarian"[Mesh] OR "Diet, Plant-Based"[Title/Abstract] OR "Plant-Based Diet*"[Title/Abstract] OR "Plant Based Diet"[Title/Abstract] OR "Plant-Based Nutrition"[Title/Abstract] OR "Plant Based Nutrition"[Title/Abstract] OR "vegetarian"[Title/Abstract] OR vegan*[Title/Abstract] OR veget*[Title/Abstract] OR plant*[Title/Abstract] OR "vegetable"[Title/Abstract] OR "dietary pattern"[Title/Abstract] OR "diet, Mediterranean"[MeSH] OR "Mediterranean"[tiab] OR "Dietary Approaches To Stop Hypertension"[Mesh] OR "Dietary Approaches To Stop Hypertension"[tiab] OR DASH[tiab] OR "Nordic diet"[Title/Abstract] OR "MIND diet"[Title/Abstract] OR "Paleolithic diet"[Title/Abstract] OR "planetary health diet index"[Title/Abstract] OR "Mediterranean-DASH Intervention for Neurodegenerative Delay"[tiab] OR portfolio diet[tiab]) AND ("Tehran lipid and glucose study"[tw] OR "TLGS"[tw])) | 73 |
| Web of Science | TS=(“Cerebrovascular Disorders” OR “Cardiovascular Diseases” OR “CVD” OR “coronary heart disease” OR “CHD” OR “ischemic heart disease” OR “myocardial infarction” OR “MI” OR “Adverse Cardiac Event*” OR “cardiovascular death” OR “cardiovascular mortality” OR “Stroke*” OR "Diabetes Mellitus" OR "cardiometabolic*" OR diabet* OR "insulin resistan*" OR "glucose intoleran*" OR "hyperglycemi*" OR "hyperglycemi*" OR “prediab*” OR "impaired glucose tolerance" OR "impaired fasting glucose" OR dyslipidemia OR dyslipidemia OR hypertension OR hypertension OR hyperlipidemia OR obesity OR overweight) AND TS=("Diet, Plant-Based" OR "Plant-Based Diet*" OR "Plant Based Diet" OR "Plant-Based Nutrition" OR "Plant Based Nutrition" OR "vegetarian" OR vegan* OR veget* OR plant* OR "vegetable" OR "dietary pattern" OR "Mediterranean" OR "Dietary Approaches To Stop Hypertension" OR DASH OR "Nordic diet" OR "MIND diet" OR "Paleolithic diet" OR "planetary health diet index" OR "Mediterranean-DASH Intervention for Neurodegenerative Delay" OR "portfolio diet") AND TS=("Tehran lipid and glucose study" OR "TLGS") | 102 |
| Scopus | TITLE-ABS-KEY(“Cerebrovascular Disorders” OR “Cardiovascular Diseases” OR “CVD” OR “coronary heart disease” OR “CHD” OR “ischemic heart disease” OR “myocardial infarction” OR “MI” OR “Adverse Cardiac Event*” OR “cardiovascular death” OR “cardiovascular mortality” OR “Stroke*” OR "Diabetes Mellitus" OR "cardiometabolic*" OR diabet* OR "insulin resistan*" OR "glucose intoleran*" OR "hyperglycemi*" OR "hyperglycemi*" OR “prediab*” OR "impaired glucose tolerance" OR "impaired fasting glucose" OR dyslipidemia OR dyslipidemia OR hypertension OR hypertension OR hyperlipidemia OR obesity OR overweight) AND TITLE-ABS-KEY("Diet, Plant-Based" OR "Plant-Based Diet*" OR "Plant Based Diet" OR "Plant-Based Nutrition" OR "Plant Based Nutrition" OR "vegetarian" OR vegan* OR veget* OR plant* OR "vegetable" OR "dietary pattern" OR "Mediterranean" OR "Dietary Approaches To Stop Hypertension" OR DASH OR "Nordic diet" OR "MIND diet" OR "Paleolithic diet" OR "planetary health diet index" OR "Mediterranean-DASH Intervention for Neurodegenerative Delay" OR "portfolio diet") AND ALL("Tehran lipid and glucose study" OR "TLGS") | 1118 |
3.3. Screening and Data Extraction
4. Results
4.1. Study Selection
4.2. Characteristics of Studies
| Author, y (Ref.) | Study Design | Dietary Exposure | Subjects | Duration (y) | Outcome Definitions | Adjustment | Results for Highest vs. Lowest Groups |
|---|---|---|---|---|---|---|---|
| Mirmiran et al., 2015 (29) | Prospective | MeDi | 2241 (18 - 74 y) | 3 | Abdominal obesity (WC ≥ 90 cm); High FSG (FSG ≥ 100 mg/dL or anti-diabetic medications); High TGs (≥150 mg/dL or lipid-lowering medications; Low HDL-C (< 40 mg/dL in men or < 50 mg/dL in women or lipid-lowering medications); High BP (SBP/DBP ≥ 130/85 or antihypertensive medications | Age, sex, smoking, physical activity, energy intake, BMI, and BMI changes | OR T3 vs. T1 for high WC: 0.74 (0.48, 1.13) a; OR T3 vs. T1 for high FSG:1.01 (0.73, 1.39); OR T3 vs. T1 for high TGs: 0.81 (0.48, 1.40); OR T3 vs. T1 for low HDL-C: 0.82 (0.48, 1.40); OR T3 vs. T1 for high BP: 0.89 (0.64, 1.22) |
| Esfandiari et al., 2017 (30) | Prospective | MeDi, DASH | 927 | 3 | IR (HOMA-IR ≥ 3.2) | Age, sex, BMI, WC, smoking, physical activity, anti-diabetic medications, serum insulin, HOMA-IR, energy intake | OR T3 vs. T1 for MeDi: 1.07 (0.60, 1.91); OR T3 vs. T1 for DASH: 0.39 (0.20,0.76) |
| Hosseini-Esfahani et al., 2017 (31) | Nested case-control study | MeDi | 1254 (> 18 y) | - | Obesity (BMI ≥ 30 kg/m2); Abdominal obesity (WC ≥ 95 cm); High WHR (WHR ≥ 0.8 in men and ≥ 0.9 in women) | Age, sex, education, smoking, physical activity, and energy intake | OR Q4 vs. Q1 for obesity: 0.67 (0.34, 1.29) b; OR Q4 vs. Q1 for abdominal obesity: 1.37 (0.75, 2.52); OR Q4 vs. Q1 for high WHR: 0.77 (0.35, 1.41) |
| Khalili-Moghadam et al., 2018 (32) | Prospective | MeDi | 2139 (20 - 70 y) | 6 | T2DM (FSG ≥ 126 mg/dL or 2-h SG ≥ 200 mg/dL, or anti-diabetic medications) | Diabetes risk score | HR T3 vs. T1: 0.48 (0.27, 0.83) |
| Ramezan et al., 2019 (33) | Nested case-control | MeDi | 561 (> 20 y) | - | T2DM (FSG ≥ 126 mg/dL or 2-h SG ≥ 200 mg/dL, or anti-diabetic medications) | Matched on age, sex, and date of data collection and controlled for family history of diabetes, WC, BMI, education, smoking, physical activity, energy intake, hypercholesterolaemia, and hypertension | OR high vs. low score: 0.93 (0.44,1.96) |
| Ramezankhani et al., 2021 (34) | Prospective | DASH | 4793 (≥ 18 y) | 6.3 | HTN (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or taking antihypertensive medications) | Age, sex, BMI, smoking, diabetes status, physical activity, TGs, family history of CVD, and salt and energy intakes | HR Q4 vs.Q1: 1.19 (0.95, 1.49) |
| Esfandiar et al., 2022 (35) | Prospective | MeDi, DASH | 6112 (≥ 18 y) | 6.6 | T2DM (FSG ≥ 126 mg/dL or 2-h SG ≥ 200 mg/dL, or antidiabetic medications) | Age, sex, diabetes risk score, physical activity, smoking, dietary fiber, and energy intake | HR Q4 vs. Q1 for MeDi:1.06 (0.87,1.30); HR Q4 vs. Q1 for DASH: 1.13 (0.88,1.46) |
| Golzarand et al., 2022 (36) | Prospective | MIND | 2863 (≥ 19 y) | 10.6 | CVD events (CHD, stroke, and CVD-related mortality) | Sex, age, BMI, smoking, SES, energy intake, diabetes, and hypertension | HR T3 vs. T1: 0.68 (0.47, 0.97) |
| Razmpoosh et al., 2022 (37) | Prospective | MeDi, DASH, MIND | 2706 (≥ 18 y) | 7.4 | HTN (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or taking antihypertensive medications) | Age, sex, physical activity, education, premature family history of CVD, smoking, BMI, prevalent of diseases, aspirin, and energy, caffeine and olive intakes | HR Q4 vs. Q1 for MeDi: 0.76 (0.53, 1.09); HR Q4 vs. Q1 for DASH: 0.99 (0.79, 1.25); HR Q4 vs. Q1 for MIND: 1.08 (0.86, 1.36) |
| Mirmiran et al., 2023 (38) | Prospective | Nordic | 2918 | 10.6 | CVD events (CHD, stroke, and CVD-related mortality) | Sex, age, BMI, smoking, dyslipidemia, diabetes, hypertension, changes in weight, and energy intake | HR Q4 vs. Q1: 0.40 (0.27, 0.60) |
| Mirmiran et al., 2023 (39) | Prospective | MeDi, DASH | 334 (≥ 21 y) | 9 | Pre-DM progression to T2DM; Pre-DM regression to NG | Age, sex, diabetes risk score, weight changes, smoking, and physical activity | OR T2DM per one-score of MeDi: 1.06 (0.86, 1.29); OR T2DM per one-score of DASH: 1.03 (0.96, 1.11); OR NG per one-score of MeDi: 1.02 (0.86, 1.29); OR NG per one-score of DASH: 0.98 (0.92, 1.06) |
| Norouzzadeh et al., 2024 (40) | Prospective | MeDi-DQI | 955 (smokers ≥ 30 y) | 8 | CVD events (CHD, stroke, and CVD-related mortality); All cause mortality | Age, SBP, FSG, occupation, BMI, physical activity, energy intake, marital status, and education | HR T3 vs. T1 for CVDs: 0.62 (0.26, 1.05); HR T3 vs. T1 for all-cause mortality: 3.45 (1.12, 10.6) |
| Malmir et al., 2025 (41) | Prospective | Potfolio | 2,188 (≥ 21 y) | 8.9 | T2DM (FSG ≥ 126 mg/dL or 2-h SG ≥ 200 mg/dL, or anti-diabetic medications) | Age, sex, BMI, energy, physical activity, and diabetic risk score | HR T3 vs. T1: 0.91 (0.63, 1.30) |
Abbreviations: BMI, Body Mass Index; BP, blood pressure; CHD, coronary heart disease; CVDs, cardiovascular diseases; DASH, dietary approaches to stop hypertension; DBP, diastolic blood pressure; FSG, fasting serum glucose; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment for insulin resistance; 2-h SG, 2-hour serum glucose; HR, hazard ratio; HTN, hypertension; IR, insulin resistance; MeDi, Mediterranean diet; MeDi-DQI, Mediterranean Dietary Quality Index; MIND, Mediterranean-DASH intervention for neurodegenerative delay; OR, odds ratio; SBP, systolic blood pressure; T2DM, type 2 diabetes; TGs, triglycerides; WC, waist circumference; WHR, waist-to-hip ratio.
a Results were reported for the Trichopoulou et al. (42) MeDi score.
b Results were reported only for a subgroup with more genetic risk alleles of FTO variants (genetic risk score ≥ 6).
